DK3207938T3 - Ctla-4-varianter - Google Patents

Ctla-4-varianter Download PDF

Info

Publication number
DK3207938T3
DK3207938T3 DK17163638.4T DK17163638T DK3207938T3 DK 3207938 T3 DK3207938 T3 DK 3207938T3 DK 17163638 T DK17163638 T DK 17163638T DK 3207938 T3 DK3207938 T3 DK 3207938T3
Authority
DK
Denmark
Prior art keywords
ctla
variants
Prior art date
Application number
DK17163638.4T
Other languages
Danish (da)
English (en)
Inventor
Ralph Minter
Julie Douthwaite
Jacques Moisan
Michael Bowen
Steven Rust
Cyril Privesentzev
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Application granted granted Critical
Publication of DK3207938T3 publication Critical patent/DK3207938T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/425—Zeins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17163638.4T 2012-05-11 2013-03-11 Ctla-4-varianter DK3207938T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261645686P 2012-05-11 2012-05-11
EP13787673.6A EP2863936A4 (en) 2012-05-11 2013-03-11 CTLA-4 VARIANTS

Publications (1)

Publication Number Publication Date
DK3207938T3 true DK3207938T3 (da) 2020-03-16

Family

ID=49551120

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17163638.4T DK3207938T3 (da) 2012-05-11 2013-03-11 Ctla-4-varianter

Country Status (17)

Country Link
US (2) US9884902B2 (enExample)
EP (2) EP2863936A4 (enExample)
JP (1) JP6228971B2 (enExample)
KR (1) KR102133060B1 (enExample)
CN (2) CN107540742B (enExample)
AU (1) AU2013260172B2 (enExample)
BR (1) BR112014026718B1 (enExample)
CA (1) CA2868748C (enExample)
DK (1) DK3207938T3 (enExample)
ES (1) ES2777778T3 (enExample)
HK (1) HK1209644A1 (enExample)
HU (1) HUE048925T2 (enExample)
MX (2) MX355234B (enExample)
PL (1) PL3207938T3 (enExample)
RU (1) RU2671465C2 (enExample)
SG (2) SG11201405968SA (enExample)
WO (1) WO2013169338A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4119857A1 (de) 1991-06-17 1992-12-24 Basf Lacke & Farben Ueberzugsmittel auf der basis von carboxylgruppenhaltigen polymeren und epoxidharzen
MX355234B (es) * 2012-05-11 2018-04-11 Medimmune Ltd Variantes de antigeno 4 del linfocito t citotoxico (ctla-4).
WO2014004780A1 (en) * 2012-06-29 2014-01-03 Bristol-Myers Squibb Company Methods for reducing glycoprotein aggregation
US9944689B2 (en) * 2013-03-07 2018-04-17 The General Hospital Corporation Human CTLA4 mutants and use thereof
CN105916883B (zh) * 2014-01-28 2019-12-03 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
WO2016115275A1 (en) 2015-01-13 2016-07-21 City Of Hope Ctla4-binding protein peptide-linker masks
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
SMT202100467T1 (it) 2015-04-17 2021-09-14 Alpine Immune Sciences Inc Proteine immunomodulatorie con affinità regolabili
CN108137659B (zh) 2015-08-21 2021-11-26 汉阳大学校产学协力团 具有预防或治疗中枢神经系统疾病作用的肽和包含其作为活性成分的药物组合物
US11351224B2 (en) 2015-08-21 2022-06-07 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Pharmaceutical composition for preventing and treating transplant rejection
WO2017034244A1 (ko) * 2015-08-21 2017-03-02 한양대학교 산학협력단 중추신경계 질환에 대한 예방 또는 치료효과를 갖는 펩타이드 및 이를 유효성분으로 하는 중추신경계 질환 예방 및 치료용 약학적 조성물
EP3350206A1 (en) * 2015-09-14 2018-07-25 Alpine Immune Sciences, Inc. Tunable variant immunoglobulin superfamily domains and engineered cell therapy
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
KR101918456B1 (ko) * 2015-12-15 2018-11-16 앱클론(주) Cd80 및 cd86에 특이적으로 결합하는 항체
SG11201808457PA (en) 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
AU2017248830B2 (en) 2016-04-15 2023-03-09 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Pd−l2バリアント免疫調節タンパク質及びその使用
MX2019010887A (es) 2017-03-16 2019-10-15 Alpine Immune Sciences Inc Proteinas inmunomoduladoras de cb80 variante y usos de estas.
CN108948194B (zh) * 2017-05-19 2023-02-17 上海药明生物技术有限公司 一种新的ctla-4单克隆抗体
EP3630843A2 (en) 2017-05-24 2020-04-08 ALS Therapy Development Institute Therapeutic anti-cd40 ligand antibodies
EP3694870A1 (en) * 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
JP7282760B2 (ja) 2017-10-18 2023-05-29 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントicosリガンド免疫調節タンパク質ならびに関連する組成物および方法
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
CA3106384A1 (en) * 2018-11-02 2020-05-07 Beijing Vdjbio Co., Ltd. Modified ctla4 and methods of use thereof
CN113727998A (zh) 2018-11-30 2021-11-30 高山免疫科学股份有限公司 Cd86变体免疫调节蛋白及其用途
WO2020210596A1 (en) * 2019-04-10 2020-10-15 University Of Kentucky Research Foundation Modified prostate apoptosis response-4 (par-4) polypeptide, and methods of production and use
CA3166299A1 (en) * 2020-01-11 2021-07-15 Paul STABACH Compositions and methods for treating, ameliorating, and/or preventing diseases or disorders caused by or associated with dnase1 and/or dnase1l3 deficiency
WO2021195418A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
CA3171795A1 (en) * 2020-04-06 2021-10-14 Jintang DU Modular synthetic receptors and methods of use
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
US12202882B2 (en) 2020-05-08 2025-01-21 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
CN112661865B (zh) * 2020-12-31 2026-04-03 厚朴生物科技(苏州)有限公司 针对新型冠状病毒的疫苗以及其应用
WO2023057994A1 (en) * 2021-10-08 2023-04-13 Kashiv Biosciences, Llc Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
AU2022361768A1 (en) * 2021-10-08 2024-05-02 Kashiv Biosciences, Llc Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography
AU2022414315A1 (en) * 2021-12-17 2024-07-25 Kashiv Biosciences, Llc An improved assay method for determining the potency of recombinant protein
TW202342510A (zh) 2022-02-18 2023-11-01 英商Rq生物科技有限公司 抗體
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69226871T3 (de) 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
WO1997047732A2 (en) * 1996-06-14 1997-12-18 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
TWI314933B (en) * 2000-05-26 2009-09-21 Bristol Myers Squibb Compan Soluble ctla4 mutant molecules and uses thereof
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2007007654A1 (ja) 2005-07-07 2007-01-18 Toshiba Lighting & Technology Corporation 放電灯点灯装置および電球形蛍光ランプ
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
CA2703263C (en) * 2007-11-01 2014-03-18 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
EP3053932B1 (en) * 2010-02-19 2020-07-22 Xencor, Inc. Novel ctla4-ig immunoadhesins
WO2011113019A2 (en) * 2010-03-12 2011-09-15 Abbott Biotherapeutics Corp. Ctla4 proteins and their uses
MX355234B (es) * 2012-05-11 2018-04-11 Medimmune Ltd Variantes de antigeno 4 del linfocito t citotoxico (ctla-4).

Also Published As

Publication number Publication date
SG10201609447XA (en) 2017-01-27
MX355234B (es) 2018-04-11
KR102133060B1 (ko) 2020-07-10
BR112014026718B1 (pt) 2021-05-18
BR112014026718A2 (pt) 2017-07-18
HUE048925T2 (hu) 2020-09-28
ES2777778T3 (es) 2020-08-06
EP2863936A1 (en) 2015-04-29
CN107540742A (zh) 2018-01-05
CN107540742B (zh) 2021-06-29
CN104302309A (zh) 2015-01-21
CA2868748C (en) 2022-07-26
US20150104450A1 (en) 2015-04-16
RU2671465C2 (ru) 2018-10-31
WO2013169338A1 (en) 2013-11-14
MX2014013092A (es) 2015-03-03
US9884902B2 (en) 2018-02-06
CA2868748A1 (en) 2013-11-14
US20180208639A1 (en) 2018-07-26
SG11201405968SA (en) 2014-11-27
KR20150014443A (ko) 2015-02-06
AU2013260172B2 (en) 2017-11-23
RU2014150092A (ru) 2016-07-10
HK1209644A1 (en) 2016-04-08
AU2013260172A1 (en) 2014-10-23
JP6228971B2 (ja) 2017-11-08
EP3207938A2 (en) 2017-08-23
EP3207938B1 (en) 2019-12-25
MX385969B (es) 2025-03-18
EP3207938A3 (en) 2017-11-01
PL3207938T3 (pl) 2020-07-13
EP2863936A4 (en) 2016-10-05
CN104302309B (zh) 2017-07-28
JP2015523328A (ja) 2015-08-13

Similar Documents

Publication Publication Date Title
NO2026005I1 (no) Dorocubicel
FIC20240017I1 (fi) Rotsanoliksitsumabi
NO2023009I1 (no) Faricimab
FIC20230015I1 (fi) Sutimlimabi
NO2022012I1 (no) amivantamab
NL301141I2 (nl) duvelisib
NL301130I2 (nl) Remimazolam
NO2019034I1 (no) lorlatinib
HUE048925T2 (hu) CTLA-4 variánsok
EP2763896A4 (en) UNMANUFACTURED AIRCRAFT WITH SEVERAL ROTORS
DK2859055T3 (da) Polymercoatings
DK2825087T3 (da) Otoscanner
DK2839013T3 (da) Ikke-disruptiv-gen-targetering
EP2809145A4 (en) CHLOROPLAST TRANSIT PEPTIDES
EP2814472A4 (en) DITHIOAMINE REDUCING AGENTS
EP2824794A4 (en) Charging cable
EP2805877A4 (en) UNDER HOOD
DK2873977T3 (da) Dobbeltdækker-rørdispenser
DE112012006109A5 (de) Okklusionsschienenanordnung
DK2854722T3 (da) Stomipose
EP2816694A4 (en) FLAT CABLE WINDING DEVICE
DK2825157T3 (da) Aminosyrelipider
EP2809729A4 (en) Siloxane polyether copolymers
BR112014022506A2 (pt) variantes de cbh1a
DE112012006214T8 (de) Wulstringwickler